by James Hong | Sep 21, 2020 | News
An analysis conducted by the Pacific Research Institute (PRI) found that the United States lost out on nearly $20 billion in potential savings since 2018 by not having access to a stronger, more competitive biosimilars market. PRI is a think tank with an emphasis on...
by James Hong | Jul 21, 2020 | News
At present, biosimilar use is relatively limited in the U.S. for several reasons, one of which is the fact that they are not well understood by many healthcare professionals and patients. As co-chairs of the Biosimilars Forum Education Committee, Dorothy McCabe,...
by James Hong | Jul 21, 2020 | News
In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars. Several trastuzumab biosimilars have been launched this year, and 6 FDA-approved adalimumab biosimilars are lined up for...
by James Hong | Jul 17, 2020 | News
The European Medicines Agency approved the first biosimilar in Europe in 2006. It was almost 10 years before the United States followed. Despite potential savings for payers and patients, biosimilar uptake in the U.S. remains limited.
by James Hong | Jul 14, 2020 | News
The House Appropriations Committee has asked for policy action by CMS that will support access to, use of, and competition from lower-cost biosimilars to provide savings for seniors, patients, and taxpayers. The request came as the committee approved the fiscal year...
Recent Comments